ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2012
EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis.Scientific reports · 2016Pooled it
- Non-small Cell Lung Cancer in Women: Experience From the National Institute of Oncology, Rabat, Morocco.Cureus · 2025Article
- Liquid biopsy for lung cancer: A cross section on the diagnostic routine experience of a referral Italian institution.The journal of liquid biopsy · 2023Article
- Prognostic role of epidermal growth factor receptor mutation status in patients with de novo lung adenocarcinoma.Translational cancer research · 2021Article
- Radiomics Signature as a Predictive Factor for EGFR Mutations in Advanced Lung Adenocarcinoma.Frontiers in oncology · 2020Article
- Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice.PloS one · 2019Article
- Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population.Journal of cancer epidemiology · 2017Article
- TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?Annals of translational medicine · 2016Article
- Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma.OncoTargets and therapy · 2016Article
- Immunotherapy for lung cancer: for whom the bell tolls?Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Investigation of the epidermal growth factor receptor mutation rate in non-small cell lung cancer patients and the analysis of associated risk factors using logistic regression.Oncology letters · 2014Article
- Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival.Radiology and oncology · 2014Article
- Article
- Article
- Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices.Clinics (Sao Paulo, Brazil) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (EGFR) mutations play a predictive role in advanced stages of non-small-cell lung cancer (NSCLC) patients. We conducted this study in order to assess EGFR status in a Portuguese population and its role in NSCLC patients' outcomes. Patients were submitted to EGFR assessment by high-resolution melting and/or direct sequencing. Kaplan-Meier curve was used to assess overall survival and progression-free survival (PFS). Two hundred forty eight out of 322 participants were assessed for EGFR status. Forty-two patients (16.9 %) presented EGFR-mutated status: one patient (2.4 %) presented exon 18; 21 patients (50 %), exon 19; one patient (2.4 %), exon 20; and 18 patients (45.2 %), exon 21 mutations, p < 0.001. PFS was not assessed (n.a.) for patient with exon 18 mutation, and for the other patients with mutations, it was 7 months (3.96-10.03) (exon 19), <1 month (exon 20), and 7 months (0-14.2) (exon 21) (p = 0.027). Overall survival (OS) was 11 months (exon 18), 11 months (1-18) (exon 19), 1 month (exon 20), and 7.5 months (2-70) (exon 21) (p = n.a). This study suggests that the EGFR mutation is herein observed in a higher proportion than expected for a Caucasian population, and OS is a little less than that published in the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.